Comparing the current results to its competitors, Calcimedica Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 5.18 %, recorded in the same quarter.
Calcimedica Inc , slower than the average decrease reported by the company's competitors of -73.93 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -73.93 %
Calcimedica Inc 's Comment on Competition and Industry Peers
The company operates in the pharmaceutical and biotechnology industry, which is characterized by rapid innovation and significant competition. Its competitors include large multinational pharmaceutical companies, established biotechnology firms, specialty pharmaceutical companies, universities, and research institutions, many of which possess greater financial, manufacturing, marketing, research, and drug development resources. Large pharmaceutical companies have extensive expertise in preclinical and clinical testing as well as regulatory approvals. Smaller or early-stage companies may also be competitors, particularly through collaborations with larger firms.
The company is developing therapeutics targeting CRAC channels, with its most advanced candidate being Auxora. Competitors developing CRAC channel inhibitors include Rhizen Pharmaceuticals AG, Vivreon Biosciences, LLC, Medshine Discovery, Inc., Eldec Pharmaceuticals, and ChemiCare srl. Competitive success will depend on factors such as efficacy, safety, pricing, reimbursement, and product convenience. Competitors may obtain regulatory approvals before the company, which could limit its commercial opportunities.
Viatris Inc operates as a global pharmaceutical company, specializing in the development, manufacturing, and distribution of a wide range of generic and branded medicines, as well as biosimilars.
Inflarx N is a company that operates on a B2B (business-to-business) model. They offer a range of services and products such as software solutions, data analytics, and consulting to businesses in the technology sector. Their revenue primarily comes from subscription fees, licensing, and consulting fees.
Prelude Therapeutics Inc is a biopharmaceutical company that focuses on developing innovative small molecule therapeutic products for cancer treatment. Their business model revolves around conducting extensive research and employing a target discovery engine to identify and validate potential drug targets. By using a combination of proprietary technologies and collaborations with academic institutions, Prelude Therapeutics aims to develop and commercialize novel oncology therapies to address unmet medical needs.
Ventyx Biosciences Inc is a biotechnology company that follows a research and development-focused business model. It aims to develop innovative biopharmaceutical products and therapeutic solutions by leveraging its expertise in various fields such as genetic engineering, drug discovery, and clinical trials. The company seeks to form strategic partnerships and licensing agreements to accelerate the commercialization of its products.
Sources:
Calcimedica Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Calcimedica Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
